Epizyme Has One FDA Approval Down, One More To Go In Coming Months [Seeking Alpha]
Epizyme, Inc. (EPZM)
Last epizyme, inc. earnings: 2/24 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
epizyme.com
Company Research
Source: Seeking Alpha
Summary Epizyme received FDA accelerated approval for TAZVERIK for the treatment of patients with relapsed/refractory epithelioid sarcoma. It is estimated that TAZVERIK, for the treatment of patients with epithelioid sarcoma, could see $100 million in peak sales. An NDA submission for potential accelerated approval of tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma had already been submitted back in December of 2019. Follicular lymphoma accounts for 20% to 30% of all non-Hodgkin's lymphoma (NHL) cases, which is why if tazemetostat is approved for this indication it will be a bigger market opportunity. EPZM FDA Accelerated Approval Based On An Unmet Medical Need I believe that the FDA approved tazemetostat because of the unmet medical need that exists with this patient population. Why do I make such a claim? There are two important reasons to highlight. The first reason is because about 45% of those with this type of cancer have metastases. That
Show less
Read more
Impact Snapshot
Event Time:
EPZM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPZM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPZM alerts
High impacting Epizyme, Inc. news events
Weekly update
A roundup of the hottest topics